Sitravatinib combined with venetoclax exerts effective synergy to eliminate acute myeloid leukemia cells with FLT3-ITD mutations

Sitravatinib combined with venetoclax exerts effective synergy to eliminate acute myeloid leukemia cells with FLT3-ITD mutations

We have previously identified sitravatinib as a potent inhibitor of FLT3, capable of overcoming resistance to gilteritinib in the treatment of acute myeloid leukemia (AML). The combination of venetoclax and FLT3 inhibitors gilteritinib and quizartinib has shown promising results in reducing leukemia...

Full description

Saved in:
Bibliographic Details
Main Authors: Jie Yang, Yvyin Zhang, Qingshan Li, Peihong Wang
Format: Article
Language:English
Published: Elsevier 2025-09-01
Series:Translational Oncology
Subjects:
FLT3-ITD mutation
BCL-2 inhibitor
Venetoclax
Sitravatinib
Synergistic effect
Online Access:http://www.sciencedirect.com/science/article/pii/S1936523325001986
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items